Alzheimer’s Drug Discovery Foundation and Harrington Discovery Institute Invite Proposals for 2020 ADDF-Harrington Scholar Award

Award expands to academic investigators in the U.K. in addition to U.S. and Canada

Update: The Letter of Intent deadline for the 2020 ADDF-Harrington Scholar Program has been extended to May 18th, 2020. Letters will be reviewed on a rolling basis starting March 31st. Full proposal deadline has been extended to August 10th.

Cleveland, Ohio – Harrington Discovery Institute at University Hospitals and the Alzheimer's Drug Discovery Foundation (ADDF) announce a joint request for proposals for the 2020 ADDF-Harrington Scholar Award. The ADDF-Harrington Scholar Award is designed to accelerate the translation of innovative research that could treat, prevent, or slow Alzheimer's disease or related dementias.

“This is our seventh year of collaborating with the Harrington Discovery Institute to offer this unique opportunity, giving academic researchers access to both funding resources as well as dedicated drug discovery and development support from a team of pharma-experienced industry leaders with a track record of bringing drugs to market,” said Dr. Howard Fillit, ADDF’s Founding Executive Director and Chief Science Officer.

The RFP is open to academic investigators at accredited medical centers, research institutions, and universities in the United States, Canada, and the United Kingdom. For the 2020 RFP, targets related to emerging therapeutic areas for dementia are of high priority, particularly:

• Proteostasis (autophagy, lysosomal biogenesis, proteasomal degradation, post-translational modification associated with proteostasis, protein folding/misfolding, ER stress, extracellular clearance)
• Neurovascular health (blood brain barrier function and integrity, cerebral hypoperfusion, nutrient supply to the brain, endothelial interaction with pericytes and astrocytes)

“Advancing treatments for neurological diseases is a key area of focus for us, and ADDF is an important part of that effort. We are pleased to expand eligibility this year to include academic investigators with novel drug programs in the U.S., Canada, and the U.K.,” said Jonathan S. Stamler, MD, President, Harrington Discovery Institute and the Robert S. and Sylvia K. Reitman Family Foundation Distinguished Chair in Cardiovascular Innovation at University Hospitals and Case Western Reserve University School of Medicine.

Award recipients will receive financial support up to $600,000 over two years, as well as drug development and project management support from Harrington Discovery Institute's Therapeutics Development team.  Proposals should offer creative science or novel approaches to treat, prevent, or slow Alzheimer's disease or related dementias. Letters of Intent will be accepted through April 20, 2020 5:00 pm EDT. Applications must be submitted online.